Dr. Marmarelis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3400 Civic Center Blvd
2 West
Philadelphia, PA 19104Phone+1 215-615-5121
Summary
- Dr. Melina Marmarelis is an oncologist in Philadelphia, PA and is affiliated with multiple hospitals in the area, including Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center. She received her medical degree from Harvard Medical School and has been in practice 4 years. She is experienced in lung cancer and medical education.
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2016 - 2019
Brigham and Women's HospitalResidency, Internal Medicine, 2013 - 2016
Harvard Medical SchoolClass of 2013
Certifications & Licensure
PA State Medical License 2016 - 2024
MA State Medical License 2013 - 2016- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Electronic Medical Record-Based Nudge Intervention to Increase Comprehensive Molecular Genotyping in Patients With Metastatic Non-Small Cell Lung Cancer: Results From ...Melina E Marmarelis, Dylan G Scholes, Tara L McWilliams, Wei-Ting Hwang, John Kosteva
JCO Oncology Practice. 2024-12-01 - Determining Line of Therapy from Real-World Data in Non-Small Cell Lung Cancer.Connor B Grady, Wei-Ting Hwang, Joshua E Reuss, Wade Iams, Amanda Cass
Pharmacoepidemiology and Drug Safety. 2024-12-01 - The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitiz...Tejas Patil, Dexiang Gao, Alexander Watson, Mandy Sakamoto, Yunan Nie
Lung Cancer. 2024-11-25
Press Mentions
Genomic Profile Availability Impact on NSCLC Patient Outcomes in Real World Study and Daily PracticeAugust 22nd, 2024- Pembrolizumab Active in Diffuse Malignant Peritoneal MesotheliomaApril 20th, 2023
- Party with a Purpose Benefits AACR and Supports Lung Cancer ResearchOctober 27th, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
